OL
LXRX icon

Orbitronix LP’s Lexicon Pharmaceuticals LXRX Stock Holding History

Orbitronix LP’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-7,143
Closed -$71K – 165
2014
Q3 		$71K Buy
+7,143
New +$76.3K 0.04% 162

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Orbitronix LP's LXRX Position: Q4 2014 in Review

Orbitronix LP sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2014, closing a stake of 7,143 shares — an estimated $71K sold.

Orbitronix LP first reported a position in LXRX in Q3 2014 and held it in 1 quarter. The position peaked at $71K in Q3 2014. 123 funds tracked by Wall St. Rank hold LXRX as of Q4 2014.

  • Orbitronix LP reported no remaining Lexicon Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Orbitronix LP sold 7,143 Lexicon Pharmaceuticals shares in Q4 2014, an estimated $71K.
  • Orbitronix LP first reported a position in Lexicon Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Orbitronix LP's Lexicon Pharmaceuticals position peaked at $71K in Q3 2014.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2014.

Based on Orbitronix LP's 13F filing for Q4 2014, filed 17 Feb 2015.